Analystreport

Arcturus Therapeutics (NASDAQ:ARCT) had its price target lowered by analysts at Piper Sandler from $140.00 to $72.00. They now have an "overweight" rating on the stock.

Arcturus Therapeutics Holdings Inc.  (ARCT) 
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.arcturusrx.com/investor-relations